Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Ongoing clinical trials, including studies specifically examining NASH outcomes, may inform future prescribing guidance
Full-dose GLP-1 therapy was designed for people with a BMI of 30+ or 27+ with comorbidities
The inclusion criteria were: a) study investigated the effects of GLP-1-based therapies on atherosclerosis by examining the effects of either exogenous GLP-1, or GLP-1 analogue, or any other serum GLP-1 elevating agent
Safety and Tolerability Key Findings: AOD-9604 has been shown to be safe and well-tolerated in clinical trials, with no reported impact on IGF-1 levels or growth hormone pathways
US$ 27.18
US$ 24.81
US$ 21.79
US$ 20.59
US$ 28.12
US$ 24.61
US$ 21.81
US$ 24.25
US$ 20.71
